Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2014 | 4.95 Million USD | 25.65% |
| 2013 | 3.94 Million USD | 155.34% |
| 2012 | 1.54 Million USD | 1166.39% |
| 2011 | 122 Thousand USD | -73.01% |
| 2010 | 452 Thousand USD | 147.28% |
| 2009 | -956 Thousand USD | 67.44% |
| 2008 | -2.93 Million USD | 1.84% |
| 2007 | -2.99 Million USD | 18.1% |
| 2006 | -3.65 Million USD | -425.47% |
| 2005 | -695 Thousand USD | 60.31% |
| 2004 | -1.75 Million USD | -207.19% |
| 2003 | -570 Thousand USD | -47.29% |
| 2002 | -387 Thousand USD | -2518.75% |
| 2001 | 16 Thousand USD | 101.94% |
| 2000 | -826 Thousand USD | -17.0% |
| 1999 | -706 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2015 Q3 | 5.4 Million USD | 3.4% |
| 2015 Q1 | 5.13 Million USD | 3.55% |
| 2015 Q2 | 5.23 Million USD | 1.91% |
| 2014 Q3 | 4.78 Million USD | 5.01% |
| 2014 Q4 | 4.95 Million USD | 3.68% |
| 2014 Q1 | 4.23 Million USD | 7.25% |
| 2014 FY | 4.95 Million USD | 25.65% |
| 2014 Q2 | 4.55 Million USD | 7.61% |
| 2013 Q2 | 1.75 Million USD | 13.29% |
| 2013 Q1 | 1.55 Million USD | 0.32% |
| 2013 Q3 | 1.83 Million USD | 4.38% |
| 2013 Q4 | 3.94 Million USD | 115.22% |
| 2013 FY | 3.94 Million USD | 155.34% |
| 2012 Q4 | 1.54 Million USD | -7.43% |
| 2012 Q2 | 1.37 Million USD | 32.63% |
| 2012 FY | 1.54 Million USD | 1166.39% |
| 2012 Q1 | 1.03 Million USD | 751.64% |
| 2012 Q3 | 1.66 Million USD | 21.12% |
| 2011 Q3 | -584 Thousand USD | -155.73% |
| 2011 Q2 | 1.04 Million USD | 36.46% |
| 2011 Q1 | 768 Thousand USD | 69.91% |
| 2011 FY | 122 Thousand USD | -73.01% |
| 2011 Q4 | 122 Thousand USD | 120.89% |
| 2010 Q2 | -172 Thousand USD | 71.09% |
| 2010 FY | 452 Thousand USD | 147.28% |
| 2010 Q4 | 452 Thousand USD | 352.0% |
| 2010 Q1 | -595 Thousand USD | 37.76% |
| 2010 Q3 | 100 Thousand USD | 158.14% |
| 2009 Q2 | -830 Thousand USD | 55.38% |
| 2009 Q1 | -1.86 Million USD | 36.65% |
| 2009 Q3 | -913 Thousand USD | -10.0% |
| 2009 FY | -956 Thousand USD | 67.44% |
| 2009 Q4 | -956 Thousand USD | -4.71% |
| 2008 FY | -2.93 Million USD | 1.84% |
| 2008 Q2 | -614 Thousand USD | 63.47% |
| 2008 Q1 | -1.68 Million USD | 43.8% |
| 2008 Q4 | -2.93 Million USD | 18.96% |
| 2008 Q3 | -3.62 Million USD | -490.07% |
| 2007 FY | -2.99 Million USD | 18.1% |
| 2007 Q2 | -1.57 Million USD | 41.94% |
| 2007 Q4 | -2.99 Million USD | 14.71% |
| 2007 Q1 | -2.71 Million USD | 25.77% |
| 2007 Q3 | -3.5 Million USD | -122.81% |
| 2006 Q2 | -4.65 Million USD | -38650.0% |
| 2006 Q4 | -3.65 Million USD | 6.02% |
| 2006 FY | -3.65 Million USD | -425.47% |
| 2006 Q1 | -12 Thousand USD | 98.27% |
| 2006 Q3 | -3.88 Million USD | 16.43% |
| 2005 Q2 | -1.44 Million USD | 28.61% |
| 2005 FY | -695 Thousand USD | 60.31% |
| 2005 Q4 | -695 Thousand USD | 13.88% |
| 2005 Q3 | -807 Thousand USD | 43.96% |
| 2005 Q1 | -2.01 Million USD | -15.19% |
| 2004 Q4 | -1.75 Million USD | 6.36% |
| 2004 FY | -1.75 Million USD | -207.19% |
| 2004 Q3 | -1.87 Million USD | 19.6% |
| 2004 Q2 | -2.32 Million USD | 15.33% |
| 2004 Q1 | -2.74 Million USD | -381.93% |
| 2003 Q3 | -667 Thousand USD | 27.1% |
| 2003 Q1 | -508 Thousand USD | -31.27% |
| 2003 FY | -570 Thousand USD | -47.29% |
| 2003 Q4 | -570 Thousand USD | 14.54% |
| 2003 Q2 | -915 Thousand USD | -80.12% |
| 2002 Q4 | -387 Thousand USD | -19.08% |
| 2002 FY | -387 Thousand USD | -2518.75% |
| 2002 Q1 | -636 Thousand USD | -4075.0% |
| 2002 Q2 | -395 Thousand USD | 37.89% |
| 2002 Q3 | -325 Thousand USD | 17.72% |
| 2001 FY | 16 Thousand USD | 101.94% |
| 2001 Q4 | 16 Thousand USD | 119.51% |
| 2001 Q2 | -247 Thousand USD | 53.83% |
| 2001 Q1 | -535 Thousand USD | 35.23% |
| 2001 Q3 | -82 Thousand USD | 66.8% |
| 2000 Q4 | -826 Thousand USD | -11900.0% |
| 2000 Q3 | 7000.00 USD | 108.86% |
| 2000 FY | -826 Thousand USD | -17.0% |
| 2000 Q1 | -361 Thousand USD | 0.0% |
| 2000 Q2 | -79 Thousand USD | 78.12% |
| 1999 FY | -706 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 378496.947% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 12.24% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 88.416% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2085.818% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1525.246% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 178.626% |
| Qrons Inc. | 351.42 Thousand USD | -1310.535% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -696.479% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 88.587% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 24389.494% |
| Skye Bioscience, Inc. | -5.72 Million USD | 186.64% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 68.553% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -20.373% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1133.548% |
| SQZ Biotechnologies Company | -36.23 Million USD | 113.679% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -121.074% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -434.628% |
| Mesoblast Limited | 55.85 Million USD | 91.126% |
| Marizyme, Inc. | 18.56 Million USD | 73.305% |
| Genus plc | 190.6 Million USD | 97.399% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -121.707% |
| Pharming Group N.V. | 109.8 Million USD | 95.486% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -476.234% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -308.357% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -628.971% |
| ContraFect Corporation | -6.02 Million USD | 182.26% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3581.697% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -329.018% |
| IMV Inc. | 7.67 Million USD | 35.376% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 9.904% |
| MultiCell Technologies, Inc. | 90.04 USD | -5505230.964% |
| ONE Bio Corp. | 9.04 Million USD | 45.166% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 775.361% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 61.71% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -262.361% |
| Q BioMed Inc. | 4.06 Million USD | -22.093% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 83.776% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -391.904% |
| Biomind Labs Inc. | 711.4 Thousand USD | -596.793% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 91.813% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -147.925% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 61.293% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1278.055% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3445.678% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -24850.924% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -125.115% |
| GB Sciences, Inc. | 1.74 Million USD | -183.692% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2797.129% |
| HST Global, Inc. | 96.79 Thousand USD | -5021.238% |
| CSL Limited | 10.52 Billion USD | 99.953% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2303.779% |
| Halberd Corporation | 144.72 Thousand USD | -3325.211% |
| Enzolytics Inc. | 981.65 Thousand USD | -404.963% |
| Agentix Corp. | 37.63 Thousand USD | -13072.65% |
| Resverlogix Corp. | 6.45 Million USD | 23.159% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 836.455% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.244% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 110.544% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 29.896% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -83.009% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 156.075% |
| AVAX Technologies, Inc. | -5.9 Million USD | 183.971% |
| Zenith Capital Corp. | 10.06 Thousand USD | -49154.769% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.467% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2373.158% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -107.751% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2913.209% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 27160.814% |
| Kadimastem Ltd | -253.1 Thousand USD | 2058.499% |
| Helix BioMedix, Inc. | -2.57 Million USD | 292.877% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 75.552% |
| BioStem Technologies, Inc. | 4.47 Million USD | -10.845% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2363.057% |
| LadRx Corporation | -2.03 Million USD | 343.412% |
| Cell Source, Inc. | 9.23 Million USD | 46.306% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -680.425% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -680.425% |
| NovAccess Global Inc. | 2.17 Million USD | -127.546% |
| Affymax, Inc. | -5.59 Million USD | 188.565% |
| Itoco Inc. | 228.3 Thousand USD | -2071.218% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3545.148% |
| Mobile Lads Corp. | 484.23 Thousand USD | -923.683% |
| CytoDyn Inc. | 20.26 Million USD | 75.535% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 766251.468% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 53583.148% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 35.674% |
| SYBLEU INC | 473.71 Thousand USD | -946.412% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -11.218% |
| International Stem Cell Corporation | 2.59 Million USD | -91.39% |
| Bioxytran, Inc. | 1.89 Million USD | -161.044% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7842.256% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -127.291% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -44.351% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 42.044% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -541.594% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 496.56% |
| Neutra Corp. | 52.18 Thousand USD | -9398.534% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 299.156% |
| PureTech Health plc | -167.19 Million USD | 102.965% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2124.025% |
| IXICO plc | -4.44 Million USD | 211.529% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 62.501% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 90.963% |
| CSL Limited | 10.52 Billion USD | 99.953% |
| Cellectis S.A. | -43.81 Million USD | 111.312% |